KRAS and neoplasm: KRAS mutation status, spectra, or transcript level were not significantly associated with the rest of the clinical parameters (age, grade of tumor, surgical radicality, chemosensitivity status, or PFI and OS, all p > .05), and this was true for the association between transcript level and stage as well.